STOCK COMPARISON
Celltrion vs Vertex Pharmaceuticals: Fair Value & Quality
Both stocks run through our valuation models. Here is how Celltrion (068270) and Vertex Pharmaceuticals (VRTX) compare, as of Aug 8, 2026.
As of Aug 8, 2026, Fair Value Calculator sees Vertex Pharmaceuticals as the less overvalued of the two: Celltrion trades at KRW 195,000 versus a fair value of KRW 76,325 (-61%), while Vertex Pharmaceuticals trades at $484 versus $279 (-42%).
Celltrion
068270.KO · KRW · Health Care
-61%
upside to fair value
overvalued
PriceKRW 195,000
Fair ValueKRW 76,325
Quality48/100
Vertex Pharmaceuticals
VRTX · USD · Health Care
-42%
upside to fair value
overvalued
Price$484
Fair Value$279
Quality74/100
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
CelltrionVertex Pharmaceuticals
Valuation
—P/E (TTM)28.8×
—P/S (TTM)10.06×
—P/B6.59×
—EV/EBITDA23.8×
0.84×PEG1.72×
0.4%Dividend yield—
KRW 714Dividend per share—
Profitability
28%Net margin36%
28%Operating margin38%
7%Return on equity24%
4%Return on assets12%
Growth
36%Revenue growth (YoY)8%
22.1%Avg. growth/yr (3Y)10.6%
17.6%Avg. growth/yr (5Y)14.2%
Balance & size
0.02×Debt / equity0.03×
$28BMarket cap$123B
mixedGrowth qualityhealthy
Celltrion leads: 5 to 4 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
Celltrionof which business quality 47 · market factors 48
Vertex Pharmaceuticalsof which business quality 77 · market factors 60
ProfitabilityMargins and returns on capital today
39
72
Quality GrowthAre margins and returns improving?
62
65
CashflowEarnings quality: real cash, not paper profit
33
79
Fin. StrengthBalance sheet, leverage, solvency risk
81
92
InvestmentDisciplined investing over empire-building
22
58
Low VolatilityCalm price path (market factor)
70
77
MomentumPrice trend over the last 3–12 months (market factor)
36
52
52W MomentumDistance to the 52-week high (market factor)
42
55
Net IssuanceBuybacks instead of dilution
32
82
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
Celltrion
DCF ModelsKRW 109,987
Earnings-BasedKRW 100,525
Dividend DiscountKRW 12,807
MultiplesKRW 80,687
Asset-BasedKRW 50,276
Growth DCFKRW 59,569
Economic ProfitKRW 59,275
Growth EarningsKRW 130,411
25 of 26 models see the stock below the current price.
Vertex Pharmaceuticals
DCF Models$429
Earnings-Based$516
Dividend Discount$7.07
Multiples$246
Asset-Based$49.27
Growth DCF$333
Economic Profit$254
Growth Earnings$672
19 of 26 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
Celltrion
Bear KRW 54,905Fair Value KRW 76,325Bull KRW 95,951
KRW 195,000 = current price (white tick)
Vertex Pharmaceuticals
Bear $210Fair Value $279Bull $900
$484 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
Celltrion · Health Care
Quality score48 · below median
Fair value upside-61% · below median
Vertex Pharmaceuticals · Health Care
Quality score74 · Top 25%
Fair value upside-42% · below median
Bottom line
As of Aug 8, 2026, Fair Value Calculator sees Vertex Pharmaceuticals as the less overvalued of the two: Celltrion trades at KRW 195,000 versus a fair value of KRW 76,325 (-61%), while Vertex Pharmaceuticals trades at $484 versus $279 (-42%).
Vertex Pharmaceuticals has the higher quality score (74/100).
See the full analysis →
More comparisons
Popular match-ups from the same sectors, all with fair value and quality score.
Free · Top-25 report
See the undervalued quality stocks every month
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.
